Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
2 patents granted to the name below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to BeOne Medicines Ltd.’s names, not what it holds today.
Patents granted
2
2 utility, 1976 to Dec 31, 2025
Granted in 2025
2
in the last year the record reads
Applications published
10
10 of them in 2025
Names they are printed under
1
a subsidiary
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name1 counted
BeOne Medicines I GmbH a subsidiary
CH, as the owner printed on each patent
10 publishedNames not counted (2)
BeiGene, Ltd.
Most of its patents print KY; this name counts in CH, US. 0 granted and 127 published under it are not counted.
BeiGene, Ltd.
Most of its patents print KY; this name counts in CH, US. 52 granted and 40 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Dec 18, 2025 | 2025/0382384 | MUC1 Antibodies and Methods of Use | Biotechnology | BeOne Medicines I GmbH |
| Nov 20, 2025 | 2025/0353858 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Organic fine chemistry | BeOne Medicines I GmbH |
| Nov 20, 2025 | 2025/0353846 | Heterocyclic Compounds | Organic fine chemistry | BeOne Medicines I GmbH |
| Nov 20, 2025 | 2025/0352659 | SELF-STABILIZING LINKER CONJUGATES | Pharmaceuticals | BeOne Medicines I GmbH |
| Nov 13, 2025 | 2025/0346597 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Pharmaceuticals | BeOne Medicines I GmbH |
| Nov 6, 2025 | 2025/0340554 | 5-Amino-1H-Pyrrolo[3,2-b]Pyridine-2-Carboxamide Derivatives as MTA-Cooperative Inhibitors of PRMT5 | Pharmaceuticals | BeOne Medicines I GmbH |
| Oct 16, 2025 | 2025/0320209 | Salts and Solid Forms of Sonrotoclax Intermediate | Organic fine chemistry | BeOne Medicines I GmbH |
| Oct 16, 2025 | 2025/0320208 | Intermediates of Sonrotoclax and the Method of Preparing the Same | Organic fine chemistry | BeOne Medicines I GmbH |
| Oct 16, 2025 | 2025/0320207 | Ketal Protected Intermediate for Sonrotoclax and Preparation Method Thereof | Organic fine chemistry | BeOne Medicines I GmbH |
| Oct 9, 2025 | 2025/0312473 | B7H3 ANTIBODY DRUG CONJUGATES | Pharmaceuticals | BeOne Medicines I GmbH |
What it applied for, 2024 to 2025: Organic fine chemistry 5 · Pharmaceuticals 4 · Biotechnology 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.